Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success "We're thrilled to add ERAS-0015 and ERAS-4001 to our pipeline. Successful in-licensing of this RAS- targeting franchise with such broad potential to address unmet needs in patients helps advance our missio ...